Polysaccharides in Ocular Drug Delivery

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Dec 28

PMID 31878298

Citations 49

Authors

Natallia Dubashynskaya

Daria Poshina

Sergei Raik

Arto Urtti

Yury A Skorik

Affiliations

Soon will be listed here.

Abstract

Polysaccharides, such as cellulose, hyaluronic acid, alginic acid, and chitosan, as well as polysaccharide derivatives, have been successfully used to augment drug delivery in the treatment of ocular pathologies. The properties of polysaccharides can be extensively modified to optimize ocular drug formulations and to obtain biocompatible and biodegradable drugs with improved bioavailability and tailored pharmacological effects. This review discusses the available polysaccharide choices for overcoming the difficulties associated with ocular drug delivery, and it explores the reasons for the dependence between the physicochemical properties of polysaccharide-based drug carriers and their efficiency in different formulations and applications. Polysaccharides will continue to be of great interest to researchers endeavoring to develop ophthalmic drugs with improved effectiveness and safety.

Citing Articles

Bioadhesive hybrid system of niosomes and pH sensitive gel for itraconazole ocular delivery: Dual approach for efficient treatment of fungal infections.

Badran M, Alsubaie A, Bekhit M, Alomrani A, Almomen A, Ibrahim M Saudi Pharm J. 2024; 32(12):102208.

PMID: 39697473 PMC: 11653644. DOI: 10.1016/j.jsps.2024.102208.

Assessment of Tamarind Seed Polysaccharide (TSP) and Hyaluronic Acid (HA) Containing Ophthalmic Solution to Maintain Tear Osmolarity, Ocular Surface Temperature (OST) and Tear Production.

Alotaibi W, Abusharha A, Pearce E, Althomali M, Afsar T, Razak S Clin Ophthalmol. 2024; 18:3503-3513.

PMID: 39624258 PMC: 11610392. DOI: 10.2147/OPTH.S493336.

Exploring Hydrogel Nanoparticle Systems for Enhanced Ocular Drug Delivery.

Arabpour Z, Salehi M, An S, Moghtader A, Anwar K, Baharnoori S Gels. 2024; 10(9).

PMID: 39330191 PMC: 11430953. DOI: 10.3390/gels10090589.

Natural Food Components as Biocompatible Carriers: A Novel Approach to Glioblastoma Drug Delivery.

Tharamelveliyil Rajendran A, Vadakkepushpakath A Foods. 2024; 13(17).

PMID: 39272576 PMC: 11394703. DOI: 10.3390/foods13172812.

Advances in Polysaccharide-Based Microneedle Systems for the Treatment of Ocular Diseases.

Bao Q, Zhang X, Hao Z, Li Q, Wu F, Wang K Nanomicro Lett. 2024; 16(1):268.

PMID: 39136800 PMC: 11322514. DOI: 10.1007/s40820-024-01477-3.

References

Balguri S, Adelli G, Majumdar S . Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016; 109:224-235. PMC: 5345266. DOI: 10.1016/j.ejpb.2016.10.015. View

Puras G, Zarate J, Diaz-Tahoces A, Aviles-Trigueros M, Fernandez E, Pedraz J . Oligochitosan polyplexes as carriers for retinal gene delivery. Eur J Pharm Sci. 2012; 48(1-2):323-31. DOI: 10.1016/j.ejps.2012.11.009. View

Al-Saedi Z, Alzhrani R, Boddu S . Formulation and In Vitro Evaluation of Cyclosporine-A Inserts Prepared Using Hydroxypropyl Methylcellulose for Treating Dry Eye Disease. J Ocul Pharmacol Ther. 2016; 32(7):451-62. DOI: 10.1089/jop.2016.0013. View

Kim Y, Chiang B, Wu X, Prausnitz M . Ocular delivery of macromolecules. J Control Release. 2014; 190:172-81. PMC: 4142116. DOI: 10.1016/j.jconrel.2014.06.043. View

Del Amo E, Urtti A . Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008; 13(3-4):135-43. DOI: 10.1016/j.drudis.2007.11.002. View

Lau C, Yu Y, Jahanmir G, Chau Y . Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges. Adv Drug Deliv Rev. 2018; 126:145-161. DOI: 10.1016/j.addr.2018.03.013. View

Giunchedi P, Conte U, Chetoni P, Saettone M . Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits. Eur J Pharm Sci. 1999; 9(1):1-7. DOI: 10.1016/s0928-0987(99)00023-8. View

Andrei G, Peptu C, Popa M, Desbrieres J, Peptu C, Gardikiotis F . Formulation and evaluation of cefuroxim loaded submicron particles for ophthalmic delivery. Int J Pharm. 2015; 493(1-2):16-29. DOI: 10.1016/j.ijpharm.2015.07.053. View

Del Amo E, Rimpela A, Heikkinen E, Kari O, Ramsay E, Lajunen T . Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2016; 57:134-185. DOI: 10.1016/j.preteyeres.2016.12.001. View

10.

Shen H, Chan E, Lee J, Bee Y, Lin T, Dusting G . Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery. Nanomedicine (Lond). 2015; 10(13):2093-107. DOI: 10.2217/nnm.15.47. View

11.

Jo D, Kim J, Lee T, Kim J . Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases. Nanomedicine. 2015; 11(7):1603-11. DOI: 10.1016/j.nano.2015.04.015. View

12.

Huang D, Chen Y, Green C, Rupenthal I . Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia. Biomaterials. 2018; 168:10-23. DOI: 10.1016/j.biomaterials.2018.03.034. View

13.

Silva M, Calado R, Marto J, Bettencourt A, Almeida A, Goncalves L . Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration. Mar Drugs. 2017; 15(12). PMC: 5742830. DOI: 10.3390/md15120370. View

14.

Conrad J, Reay W, Polcyn R, Robinson J . Influence of tonicity and pH on lacrimation and ocular drug bioavailability. J Parenter Drug Assoc. 1978; 32(4):149-61. View

15.

Badiee P, Varshochian R, Rafiee-Tehrani M, Dorkoosh F, Khoshayand M, Dinarvand R . Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment. J Biomed Mater Res A. 2018; 106(8):2261-2271. DOI: 10.1002/jbm.a.36424. View

16.

Koelwel C, Rothschenk S, Fuchs-Koelwel B, Gabler B, Lohmann C, Gopferich A . Alginate inserts loaded with epidermal growth factor for the treatment of keratoconjunctivitis sicca. Pharm Dev Technol. 2008; 13(3):221-31. DOI: 10.1080/10837450801949566. View

17.

Kaur I, Kakkar S . Nanotherapy for posterior eye diseases. J Control Release. 2014; 193:100-12. DOI: 10.1016/j.jconrel.2014.05.031. View

18.

Urtti A . Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006; 58(11):1131-5. DOI: 10.1016/j.addr.2006.07.027. View

19.

Jung J, Desit P, Prausnitz M . Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing. Invest Ophthalmol Vis Sci. 2018; 59(5):2069-2079. PMC: 5909801. DOI: 10.1167/iovs.17-23758. View

20.

Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z . Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B. 2017; 7(3):281-291. PMC: 5430571. DOI: 10.1016/j.apsb.2016.09.001. View